公开(公告)号：US06685962B2

公开(公告)日：2004-02-03

申请号：US10157325

申请日：2002-05-29

申请人： Michael Friedman ,  Eytan Klausner ,  Eran Lavy ,  Amnon Hoffman

发明人： Michael Friedman ,  Eytan Klausner ,  Eran Lavy ,  Amnon Hoffman

IPC分类号： A61K952

CPC分类号： A61K9/2086

摘要： Pharmaceutical gastroretentive drug delivery systems for the controlled release of an active agent in the gastrointestinal tract are disclosed, which comprise: (a) a single- or multi-layered matrix comprising a polymer that does not retain in the stomach more than a conventional dosage form selected from (1) degradable polymers that may be hydrophilic polymers not instantly soluble in gastric fluids, enteric polymers substantially insoluble at pH less than 5.5 and/or hydrophobic polymers and mixtures thereof; (2) non-degradable polymers; and any mixtures of (1) and (2); (b) a continuous or non-continuous membrane comprising at least one polymer having a substantial mechanical strength; and (c) a drug; wherein the matrix when affixed or attached to the membrane prevents evacuation from the stomach of the delivery system for a period of time of from about 3 to about 24 hours.

摘要翻译： 公开了用于在胃肠道中控制释放活性剂的药物胃滞留药物递送系统，其包括：（a）包含不比常规剂型保留在胃中的聚合物的单层或多层基质 选自（1）可以是亲水性聚合物的可降解聚合物，其不能立即溶于胃液，在pH小于5.5时基本上不溶解的肠溶聚合物和/或疏水性聚合物及其混合物; （2）不可降解聚合物; 和（1）和（2）的任何混合物; （b）包含至少一种具有相当机械强度的聚合物的连续或非连续膜; 和（c）药物; 其中当固定或连接到膜上时的基质防止从输送系统的胃排出约3至约24小时的时间。

公开(公告)号：US11052043B2

公开(公告)日：2021-07-06

申请号：US14007331

申请日：2012-03-28

申请人： Michael Friedman ,  Amnon Hoffman ,  Eran Lavy

发明人： Michael Friedman ,  Amnon Hoffman ,  Eran Lavy

IPC分类号： A61K9/06 ,  A61K31/65 ,  A61K31/43 ,  A61K31/546 ,  A61K9/10 ,  A61K31/496 ,  A61K47/10 ,  A61K9/00

摘要： A composition which comprises a biologically active agent and a polymer that exhibits a reverse thermal gelation at a physiological temperature, in a carrier, and in which the active agent is in an undissolved form is disclosed herein. Further disclosed herein are methods utilizing the compositions for treating subjects, including non-human subjects, as well as kits for preparing and using a composition. The composition is preferably a sustained release formulation, and is particularly useful for treating animals, where single-dose treatment is desired.

公开(公告)号：US20140018323A1

公开(公告)日：2014-01-16

申请号：US14007331

申请日：2012-03-28

申请人： Michael Friedman ,  Amnon Hoffman ,  Eran Lavy

发明人： Michael Friedman ,  Amnon Hoffman ,  Eran Lavy

IPC分类号： A61K47/10 ,  A61K9/06

CPC分类号： A61K9/06 ,  A61K9/0024 ,  A61K9/10 ,  A61K31/43 ,  A61K31/496 ,  A61K31/546 ,  A61K31/65 ,  A61K47/10

摘要： A composition which comprises a biologically active agent and a polymer that exhibits a reverse thermal gelation at a physiological temperature, in a carrier, and in which the active agent is in an undissolved form is disclosed herein. Further disclosed herein are methods utilizing the compositions for treating subjects, including non-human subjects, as well as kits for preparing and using a composition. The composition is preferably a sustained release formulation, and is particularly useful for treating animals, where single-dose treatment is desired.

摘要翻译： 本文公开了一种组合物，其包含生物活性剂和在生理温度下，在载体中表现出反向热凝胶化，并且其中活性剂为未溶解形式的聚合物。 本文进一步公开的是利用组合物治疗受试者，包括非人受试者的方法，以及制备和使用组合物的试剂盒。 组合物优选为持续释放制剂，并且特别可用于治疗需要单剂量治疗的动物。

公开(公告)号：US20140328895A1

公开(公告)日：2014-11-06

申请号：US14007347

申请日：2012-03-25

申请人： Michael Friedman ,  Doron Steinberg ,  Eran Lavy

发明人： Michael Friedman ,  Doron Steinberg ,  Eran Lavy

IPC分类号： A61L29/08 ,  A61L31/16 ,  A61K31/4425 ,  A61K47/32 ,  A61K31/09 ,  A61L29/16 ,  A61K47/38 ,  A61K47/10 ,  A61K31/155 ,  A61K31/4174

CPC分类号： A61L29/085 ,  A61K9/0041 ,  A61K9/7015 ,  A61K31/085 ,  A61K31/09 ,  A61K31/155 ,  A61K31/4164 ,  A61K31/4174 ,  A61K31/4425 ,  A61K47/10 ,  A61K47/32 ,  A61K47/38 ,  A61L27/34 ,  A61L27/54 ,  A61L29/16 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/602 ,  A61L2420/02 ,  A61L2420/06

摘要： The present invention discloses a liquid precursor composition adapted for application on a on a desired surface, this composition comprising: a. at least one therapeutic agent suitable for the treatment or prevention of a disorder or pathological condition, wherein said disorder or pathological condition excludes oral disorders, b. at least one acidic-pH sensitive polymer, c. at least one hydrophobic polymer, and d. a pharmaceutically acceptable volatile solvent, wherein a weight ratio between the at least one hydrophobic polymer and the at least one acidic-pH sensitive polymer is larger than 1.

摘要翻译： 本发明公开了适用于所需表面上的液体前体组合物，该组合物包含：a。 至少一种适用于治疗或预防病症或病理状况的治疗剂，其中所述病症或病理状况排除口腔障碍，b。 至少一种酸性pH敏感聚合物，c。 至少一种疏水性聚合物，和d。 药学上可接受的挥发性溶剂，其中所述至少一种疏水性聚合物和所述至少一种酸性pH敏感聚合物之间的重量比大于1。